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Background: This study aimed to identify pathogenic variants of PRSS1, SPINK1, CFTR, 
and CTRC genes in Korean patients with idiopathic pancreatitis.
Methods: The study population consisted of 116 Korean subjects (65 males, 51 females; 
mean age, 30.4 yr, range, 1-88 yr) diagnosed with idiopathic chronic pancreatitis (ICP), 
idiopathic recurrent acute pancreatitis (IRAP), or idiopathic acute pancreatitis (IAP). We 
analyzed sequences of targeted regions in the PRSS1, SPINK1, CFTR, and CTRC genes, 
copy numbers of PRSS1 and SPINK1, and clinical data from medical records. 
Results: We identified three types of pathogenic PRSS1 variants in 11 patients, including 
p.N29I (n=1), p.R122H (n=1), and p.G208A (n=9). Sixteen patients exhibited heterozy-
gous pathogenic variants of SPINK1, including c.194+2T>C (n=12), p.N34S (n=3), and 
a novel pathogenic splicing variation c.194+1G>A. A heterozygous CFTR p.Q1352H 
pathogenic variant was detected in eight patients. One patient carried a heterozygous 
CTRC p.P249L pathogenic variant, which is a known high-risk variant for pancreatitis. All 
patients had normal PRSS1 and SPINK1 gene copy numbers. Weight loss occurred more 
frequently in patients carrying the p.G208A pathogenic variant, while pancreatic duct 
stones occurred more frequently in patients with the c.194+2T>C pathogenic variant.
Conclusions: Pathogenic variants of PRSS1, SPINK1, and CFTR were associated with id-
iopathic pancreatitis, while pathogenic variants of CTRC were not. Copy number variations 
of PRSS1 and SPINK1 were not detected. 
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INTRODUCTION
Pancreatitis is characterized by inflammation of the pancreas 
that progresses from acute (sudden onset; duration less than 6 
months) to rec urrent acute (more than one episode of acute 
pancreatitis) to chronic (duration more than 6 months). Re-
peated episodes of acute pancreatitis can progressively lead to 
irreversible exocrine and endocrine pancreatic insufficiency. 
Gallstones and alcohol abuse are the two most common causes 
of acute pancreatitis, and alcohol abuse is the most frequent 
cause of chronic pancreatitis. However, the etiology of 10-30% 
of acute or chronic pancreatitis cases cannot be readily identi-
fied and these cases are classified as idiopathic pancreatitis [1]. 
In 1996, the cationic trypsinogen gene PRSS1 (OMIM 
#276000; NM_002769.4) was identified as a cause of heredi-
tary pancreatitis (HP) and some cases of idiopathic chronic 
pancreatitis (ICP) [2, 3]. HP is a rare autosomal dominant disor-
der characterized by recurrent attacks of pancreatitis, with ap-
proximately 80% penetrance by 20 yr of age [4]. PRSS1 en-
codes cationic trypsinogen, the most abundant isoform of tryp-
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sinogen in human pancreatic juice. Pathogenic PRSS1 variants 
alter the activation and degradation of cationic trypsinogen by 
chymotrypsin C (CTRC; OMIM 601405; NM_007272.2) [5]. 
The p.R122H and p.N29I of PRSS1 have been identified as the 
most common pathogenic variants that exhibit high penetrance 
and follow the autosomal dominant pattern of pancreatitis [6]. 
Gain-of-function pathogenic PRSS1 variants, including patho-
genic missense mutations and pathogenic copy number varia-
tions (CNV) such as gene duplication or triplication, have been 
identified in ICP patients [7]. 
In addition, pathogenic variants of the cystic fibrosis trans-
membrane conductance regulator (CFTR; OMIM 602421; 
NM_000492.3) [8, 9], serine protease inhibitor Kazal type 1 
(SPINK1; OMIM 167790; NM_003122.4) [10, 11], and CTRC 
genes have been described in both ICP and alcoholic CP [12]. 
Therefore, mutational analysis may reveal a genetic basis for id-
iopathic pancreatitis in a significant proportion of patients. In-
deed, genetic testing may play a critical role in the evaluation 
and management of pancreatitis. 
The four above-mentioned genes have been the most exten-
sively studied genes to date that promote or cause pancreatitis. 
However, few reports [13, 14] have studied all four genes simul-
taneously in idiopathic pancreatitis. In addition, pathogenic vari-
ants of CTRC and CNVs of PRSS1 and SPINK1 have not been 
evaluated in Korean patients with pancreatitis. In this study, we 
identify the spectrum and frequency of pathogenic variants of 
PRSS1, SPINK1, CFTR, and CTRC and CNVs of PRSS1 and 
SPINK1, and determine their association with the clinical course 
of idiopathic pancreatitis in Korean patients. 
METHODS 
1. Patients
The study population consisted of 116 Korean subjects (65 
males, 51 females; mean age, 30.4 yr, range, 1-88 yr) diag-
nosed with ICP (n=59), idiopathic recurrent acute pancreatitis 
(IRAP, n=14), or idiopathic acute pancreatitis (IAP, n=43). 
Only patients with pancreatitis confirmed by their referring phy-
sicians from July 2008 to December 2015 were included in this 
study. Written informed consent was obtained from each pa-
tient, and this study was approved by the Institutional Review 
Board of Gangnam Severance hospital, Seoul, Korea. Clinical 
information was obtained for 84 of the patients via a retrospec-
tive review of medical records. Imaging examination, including 
endoscopic retrograde cholangiopancreatography (ERCP), com-
puted tomography (CT), magnetic resonance imaging (MRI), ul-
trasonography, and magnetic resonance cholangiopancreatog-
raphy (MRCP), was performed to detect changes in the pancre-
atic duct (stenosis or dilation). The majority of patients (58 of 
84, 69%) expressed abdominal pain, four patients exhibited 
weight loss, two patients had abdominal discomfort, and one 
patient had portal hypertension as their chief complaint on the 
first doctors’ visit. Interestingly, 20 patients were diagnosed with 
chronic pancreatitis during medical examination or during eval-
uation for co-morbidity. During the evaluation for pancreatitis, 
eight patients were diagnosed with pancreatic cancer and one 
was diagnosed with intraductal papillary mucinous neoplasm. 
The majority of pancreatic cancer patients had CP (n=6). Imag-
ing examination detected pancreatic duct changes (stenosis or 
dilation) in 26 patients, and pancreatic duct stones, pancreatic 
calcification, and pseudocysts in nine patients each. In addition, 
annular pancreas, pancreatic divisum, and anomalous union of 
pancreaticobiliary duct (AUPBD) were detected in one patient 
each (Table 1).  
2. DNA isolation
Genomic DNA was extracted from EDTA-treated whole blood 
samples by using a QIAamp DNA Blood Mini kit (Qiagen, 
Hilden, Germany), on a QIAcube automatic nucleic acid extrac-
tion instrument (Qiagen), according to the manufacturer’s in-
structions.
Table 1. Clinical characteristics of patients with idiopathic pancre-
atitis
Age (years, mean±SD)* 30.4±18.6
Male, N (%)* 65 (56.0%)
Clinical findings, N (%)†
   Pain 58 (69.0%)
   Weight loss 4 (4.8%)
   Abdominal discomfort 2 (2.4%)
   Portal hypertension 1 (1.2%)
   Steatorrhea 1 (1.2%)
Imaging Findings, N (%)†
   Pancreatic duct stenosis or dilation 26 (31.0%)
   Pancreatic duct stones 9 (10.7%)
   Pancreatic duct pseudocyst 9 (10.7%)
   Pancreatic duct calcification 9 (10.7%)
   Others‡ 3 (3.6%)
*Age and gender information were acquired from the entire study population 
(n=116); †Clinical and imaging findings were obtained from only 84 pa-
tients; ‡Included annular pancreas, pancreatic divisum, and anomalous 
union of pancreaticobiliary duct.
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3.  Analyses of PRSS1, SPINK1, CFTR, and CTRC pathogenic 
variants
Genomic DNA was amplified by PCR and sequenced by the 
Sanger method. Sequence analysis of PRSS1 (exon 2, 3, and 5), 
SPINK1 (exon 3), CFTR (exon 3 and 7), and CTRC (exon 25 for 
Q1352H) was performed on an ABI 3500xL system (Applied 
Biosystems, Foster City, CA, USA). 
4. Detection of copy number variations 
Multiplex ligation-dependent probe amplification (MLPA) was 
performed to assess PRSS1 and SPINK1 CNVs, using an MLPA 
kit (SALSA MLPA KIT P242 Pancreatitis, MRC Holland, Amster-
dam, The Netherlands) according to the manufacturer’s instruc-
tions. MLPA fragment analysis data were generated on an ABI 
3500xL system (Applied Biosystems) and analyzed by using 
GeneMarker (SoftGenetics, State College, PA, USA).
5. Statistical analysis 
The Student’s t-test (unpaired) was performed for comparing 
quantitative data, and χ2 test or Fisher’s exact test was per-
formed for analyzing qualitative data. A P value less than 0.05 
was considered statistically significant. SPSS version 20 (IBM, 
Armonk, NY, USA) was used for statistical analysis. We exam-
ined whether the clinical course of pathogenic variant-positive 
and pathogenic variant-negative patients was significantly differ-
ent. We reviewed the clinical course, including the clinical fea-
tures and imaging findings. 
RESULTS
1. Genetic analysis
All 26 idiopathic pancreatitis cases (22.4%) carried at least one 
causative or contributory genotype (Table 2). We found three 
types of pathogenic PRSS1 variants in 11 patients, including 
p.N29I (n=1), p.R122H (n=1), and p.G208A (n=9). Among 
patients with PRSS1 p.G208A, SPINK1 c.194+2T>C (n=2), 
SPINK1 p.N34S (n=1), and CFTR p.Q1352H (n=4) were also 
detected. We found three types of heterozygous pathogenic 
SPINK1 variants in 16 patients, including c.194+2T>C (n=12), 
p.N34S (n=3), and c.194+1G>A (n=1). Two patients with 
SPINK1 c.194+2T>C and p.N34S also had CFTR p.Q1352H. 
A single heterozygous CFTR p.Q1352H pathogenic variant was 
detected in eight patients. One patient carried a heterozygous 
CTRC p.P249L (rs142560329) variant, which was previously 
established to be a high-risk CTRC variant by functional analysis 
[15]. A rare CTRC p.R246C variant was also detected in one 
patient. PRSS1 and SPINK1 gene copy numbers were normal 
in all patients tested (n=93).
2. Association of pathogenic variants with clinical course
We associated genotype data with clinical data from 84 patients 
(Table 3). The c.194+2T>C pathogenic variant in SPINK was 
the most common variant, followed by the p.G208A pathogenic 
variant in PRSS1 and the p.Q1352H pathogenic variant in 
CFTR. However, only pathogenic variants of PRSS1 and SPINK1 
were associated with clinical courses. Weight loss occurred 
more frequently in patients with the p.G208A pathogenic variant 
(2.6% vs 25.0%; P =0.044), while pancreatic duct stones oc-
curred more frequently in patients with the c.194+2T>C patho-
genic variant (6.8% vs 40.0%; P =0.01). Although the differ-
ence was not statistically significant, pancreatic stenosis oc-
curred more frequently in patients carrying the CFTR p.Q1352H 
pathogenic variant (28.2% vs 66.7%). Pancreatic duct stones 
were more common in patients with the PRSS1 p.G208A patho-
genic variant (7.9% vs 37.5%). We did not find an association 
between any of the pathogenic gene variants (PRSS1, SPINK1, 
CFTR, and CTRC) and an earlier age of symptom onset. Addi-
tionally, the dosage of pathogenic variants was not associated 
with the clinical course. Among eight pancreatic cancer pa-
tients, two had pathogenic variants (SPINK c.194+1G>A and 
CFTR p.Q1352H, respectively). However, the clinical course of 
pathogenic variant-positive patients was not different from that 
of pathogenic variant-negative patients, except for those diag-
nosed with cancer at a younger age. 
Table 2. Pathogenic variants of PRSS1, SPINK1, CFTR, and CTRC 
in patients with idiopathic pancreatitis
Gene pathogenic variant, N (%)
PRSS1
   p.N29I 1 (0.9%)
   p.R122H 1 (0.9%)
   p.G208A 9 (7.8%)
SPINK1
   p.N34S 3 (2.6%)
   c.194+1G>A 1 (0.9%)
   c.194+2T>C 12 (10.3%)
CFTR
   p.Q1352H 8 (6.9%)
CTRC
   p.P249L 1 (0.9%)
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DISCUSSION
Schnur et al [16] reported that PRSS1 p.G208A pathogenic 
variant was rare and predominant in Asia, and caused a moder-
ate secretion defect [16]. Lee et al [17] reported that it was the 
most common pathogenic variant detected in Korean children 
with HP. The p.G208A pathogenic variant is considered a milder 
pathogenic variant than the PRSS1 ‘classic pathogenic variant,’ 
p.R122H, because of its association with alcoholic CP and the 
co-existence of the CTRC p.R29Q and the SPINK1 p.N34S in 
some patients [18]. Indeed, some patients carrying the p.
G208A pathogenic variant also harbored pathogenic variants of 
SPINK1 or CFTR. In a previous study, a patient with pancreatitis 
and carrying the p.G208A pathogenic variant also harbored 
p.F508del and p.Q1352H pathogenic variants of CFTR [19]. 
Importantly, our results show that the PRSS1 p.G208A patho-
genic variant is associated with idiopathic pancreatitis in Korean 
children and adults. The patients carrying the p.G208A patho-
genic variant presented weight loss more frequently compared 
with patients lacking this pathogenic variant. Weight loss can 
occur owing to loss of pancreatic function or decreased food 
consumption due to postprandial pain. 
Patients with pathogenic variants of PRSS1 are at a greater 
risk of developing pancreatic cancer, owing to the prolonged 
history of CP [20]. While we were unable to identify any associa-
tion of pathogenic variants with the development of pancreatic 
cancer, it should be noted that the two cancer patients with 
pathogenic variants were younger than the other patients with-
out variants (41.5 yr vs 59.8 yr, P =0.033). Therefore, we be-
lieve that the pathogenic variants responsible for CP might play 
a role in the early development of pancreatic cancer.
SPINK1 is a potent anti-protease that functions as a major in-
activator of intrapancreatic trypsin. SPINK1 pathogenic variants 
act as a risk modifier in recurrent acute pancreatitis, thereby 
lowering the threshold for developing chronic pancreatitis in-
duced by other genetic or environmental factors [21]. In agree-
ment with previous studies [22, 23], the frequency of the 
SPINK1 c.194+2T>C pathogenic variant was much higher than 
the frequency of the p.N34S heterozygous pathogenic variant 
that occurs commonly in western countries [24]. The c.194+ 
2T>C pathogenic variant resulted in patients manifesting a 
more complicated disease pathology than patients lacking this 
pathogenic variant. A novel pathogenic splicing variation, c.194+ 
1G>A, was found in a 41 yr old man diagnosed with pancreatic 
duct stones and CP. This variant affects an intron splice donor 
site by altering the highly conserved GT dinucleotide. Although 
the actual effect of the SPINK1 variant c.194+ 1G>A was not 
investigated, this novel splicing variation was classified as ‘likely 
pathogenic’ by the ACMG standards and guidelines for the in-
terpretation of sequence variants [25].
Masson et al reported gain-of-function duplication and tripli-
cation of an approximately 605-kb segment containing PRSS1 
and PRSS2 on chromosome 7q34 in French patients with he-
reditary or idiopathic CP [7, 26]. In addition, they identified two 
large genomic deletions in SPINK1 that caused chronic pancre-
atitis [27, 28]. Recently, CNVs of PRSS1 were also reported in 
Chinese ICP patients, wherein four patients carried only one 
copy and one carried five [13]. In contrast, no CNVs were iden-
tified in this study.  
Pancreatic insufficiency in patients with cystic fibrosis is due 
to pathogenic variants of the CFTR gene, such as p.F508del, 
p.R117H, and p.N1303K, which result in a defective chloride 
channel and subsequent pancreatic duct obstruction. Patho-
genic variants of CFTR are associated with chronic pancreatitis 
Table 3. Association of pathogenic variants with clinicopathological data from 84 patients








   Positive 1/7 0.299 2/7 0.628 3/7 0.024
   Negative 3/77 24/77 6/77
PRSS1 p.G208A
   Positive 2/7 0.033 3/7 0.671 2/7 0.162
   Negative 2/77 23/77 7/77
CFTR p.Q1352H
   Positive 1/6 0.261 4/6 0.071 1/6 0.505
   Negative 3/78 22/78 8/78
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without any evidence of cystic fibrosis [8, 9]. A previous study 
[29] reported that the pathogenic CFTR p.Q1352H variant in 
the Korean population was significantly higher in patients with 
bronchiectasis and chronic pancreatitis than in the control 
group. In addition, the authors reported that the pathogenic 
p.Q1352H variant decreased mature CFTR protein expression 
by 73% and chloride current activity by 71%. Therefore, they 
suggested that the p.Q1352H pathogenic variant was strongly 
associated with respiratory and pancreatic disease among Kore-
ans. CFTR p.Q1352H variant observed in eight patients. The al-
lele frequency in control groups from Jang et al [30] was 1.2%, 
which is similar to publicly accessible data (0.49 to 2.4% from 
1,000 genomes; 1.3% from ExAC Browser). The pathogenic 
p.Q1352H variant was significantly associated with ICP (P = 
0.039) in our study.
Rosendahl et al [12] analyzed CTRC gene variants in a Ger-
man cohort of over 300 patients with idiopathic or hereditary CP 
and revealed that alterations in CTRC predispose patients to 
pancreatitis by decreasing the protective, trypsin-degrading ac-
tivity of this enzyme. Pathogenic CTRC variants in exons 3 and 
7 were also associated with CP in Europe and India [12, 31], al-
though the spectrum of the pathogenic variants was different 
between the two populations. Interestingly, the spectrum and 
distribution of pathogenic CTRC variants were different within 
Asian subjects. Masamune et al [32] found five novel missense 
variants (8/506) in Japanese CP patients. However, only three 
variants, including p.R29Q, p.S239C, and p.R254W, were 
shown to be functionally deleterious [15, 33]. A cohort study 
with Chinese pediatric ICP patients [13] did not find any patho-
genic variants of CTRC, whereas we identified one patient with 
the pathogenic p.P249L variant. Taken together, CTRC patho-
genic variants are uncommon and do not play a significant role 
in idiopathic pancreatitis in the Korean population. 
 The current study had several limitations. First, we could not 
determine the natural history of IP complications based on 
these data and the limited subgroups. Additionally, we se-
quenced only targeted regions of the PRSS1, SPINK1, CFTR, 
and CTRC genes. However, we were able to identify the patho-
genic variant spectrums of these genes in Korean IP patients, 
and we were able to associate pathogenic variants with clinico-
pathological data.
In conclusion, we report that PRSS1, SPINK1, and CFTR 
pathogenic variants were associated with IP, whereas patho-
genic variants of CTRC were not associated with this disease. 
We did not detect CNVs for PRSS1 and SPINK1 in Korean pa-
tients with idiopathic pancreatitis. Patients with pathogenic vari-
ants of PRSS1 and SPINK1 presented a more severe clinical 
course, implying that genetic risk assessment may be useful for 
identifying individuals likely to develop severe CP, and develop 
targeted therapy for slowing or preventing disease progression. 
Larger prospective studies to evaluate the clinical impact of 
pathogenic variants are needed, along with comprehensive 
analyses by next generation sequencing to identify novel pan-
creatitis-associated genes.
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